ライフサイエンスコーパス: thrombopoietin

1 nced reactive myeloproliferative response to thrombopoietin.

2 n, soluble transferrin receptor (sCD71), and thrombopoietin.

3 pon stimulation of primary megakaryocytes by thrombopoietin.

4 es, and show altered biochemical response to thrombopoietin.

5 an CD34(+) cells cultured in the presence of thrombopoietin.

6 reduced levels of plasma erythropoietin and thrombopoietin.

7 cktail of stem cell factor, flt3 ligand, and thrombopoietin.

8 ured in the presence of stem cell factor and thrombopoietin.

9 ption factor scl and c-mpl, the receptor for thrombopoietin.

10 unction, and raised serum erythropoietin and thrombopoietin.

11 -6, stem cell factor (SCF), Flt3 ligand, and thrombopoietin.

12 cting cytokines kit ligand, flt3 ligand, and thrombopoietin.

13 two doses of 1.2 microg/kg recombinant human thrombopoietin.

14 feration of BaF3/Mpl cells in the absence of thrombopoietin.

15 and controls the proliferative responses to thrombopoietin.

16 tem-cell-derived hematopoietic cultures with thrombopoietin, a multistage cytokine.

17 Thrombopoietin affects nearly all aspects of platelet pr

18 ecular and cellular mechanisms through which thrombopoietin affects platelet production provide new i

19 prove response rates, as recently shown with thrombopoietin analogs.

20 lear cells were incubated in the presence of thrombopoietin and 10% plasma from either ITP patients (

21 Thrombopoietin and basic fibroblast growth factor are id

22 expression profiles correlated with that of thrombopoietin and found that genes whose expression ass

23 egulation occurs with the receptors for Epo, thrombopoietin and growth hormone but not with the recep

24 binant hemopoietic growth factors, including thrombopoietin and interkeukin-11, may be useful future

25 e potential of hemopoietic growth factors (, thrombopoietin and interleukin-11) to prevent or treat n

26 Silencing thrombopoietin and interleukin-6 abrogated thrombocytosi

27 Plasma levels of thrombopoietin and interleukin-6 were significantly elev

28 Thrombopoietin and its receptor (Mpl) support survival a

29 ereas megakaryocyte progenitors treated with thrombopoietin and LY294002 showed both a G(1) and a G(2

30 BaF3/Mpl cells treated with thrombopoietin and LY294002 were blocked in G(1), wherea

31 development of antibodies against endogenous thrombopoietin and subsequent refractory thrombocytopeni

32 gulate the expression of genes such as THPO (thrombopoietin) and ATP5B (ATP synthase, H+ transporting

33 x were reduced, while reticulated platelets, thrombopoietin, and bone marrow megakaryocyte colony-for

34 r angiogenic growth factors (angiopoietin-2, thrombopoietin, and epidermal growth factor).

35 ure containing IL-3, IL-6, stem cell factor, thrombopoietin, and Flt3 ligand induced Ccn3/Nov mRNA ov

36 ng STAT5 phosphorylation in response to IL3, thrombopoietin, and GM-CSF.

37 Because the erythropoietin, thrombopoietin, and granulocyte colony-stimulating facto

38 topoietic cell receptors for erythropoietin, thrombopoietin, and granulocyte colony-stimulating facto

39 ter exhibited reduced proplatelet formation, thrombopoietin, and integrin signaling.

40 tly of the key regulator of megakaryopoiesis thrombopoietin, and may occur during situations of acute

41 n mice by phlebotomy or by administration of thrombopoietin, and ultrastructural analysis was perform

42 h the recent cloning and characterization of thrombopoietin, appreciation of the molecular events sur

43 being given a new spin, newer agents such as thrombopoietins are showing significant promise.

44 ifferentiation process driven by the hormone thrombopoietin by which haematopoietic progenitor cells

45 ic progenitor cells, during pre-expansion by thrombopoietin, c-kit ligand, and FLT-3 ligand, on recom

46 ved platelets derived from recombinant human thrombopoietin can provide a viable strategy to minimise

47 We identify roles for thrombopoietin, CCL3, and direct cell-cell interactions

48 platelet and red blood cell variability, and thrombopoietin/cellular myeloproliferative leukemia viru

49 s harvested from healthy donors treated with thrombopoietin could provide larger increases in platele

50 yocytes may reduce metastasis, we found that thrombopoietin-deficient mice exhibited a 90% relative d

51 imulated hematopoiesis both in wild-type and thrombopoietin-deficient mice.

52 rapidly overgrown by a unique population of thrombopoietin-dependent blasts that express immature ma

53 NK mutants displayed augmented and sustained thrombopoietin-dependent growth and signaling.

54 Transfusion of thrombopoietin-derived autologous platelets might provid

55 ssful search to purify and molecularly clone thrombopoietin did not begin until the oncogene v-mpl wa

56 Strikingly, thrombopoietin-differentiated DAMI cells, which represen

57 ation of transforming growth factor-beta1 in thrombopoietin-driven experimental myelofibrosis in mice

58 response to stem cell factor and diminished thrombopoietin-evoked Erk activation.

59 Recombinant human thrombopoietin facilitated collection of multiple units

60 ne marrow cells grown in liquid culture with thrombopoietin failed to develop polyploid cells greater

61 The combination of thrombopoietin, Flt3 ligand, and stem cell factor upregu

62 here that the 2 cytokines interleukin 3 and thrombopoietin have the ability to expand hematopoietic

63 The recombinant thrombopoietins have been shown to be effective stimulat

64 ve reduced activation of Rap1 in response to thrombopoietin, IGF-1,ADP, SFLLRN, and thrombin.

65 ys with OP9 stromal cells in the presence of thrombopoietin, IL-6, and IL-11 resulted in the developm

66 The levels of thrombopoietin, immature platelet fraction, and mean pla

67 rmined by quantification of platelet counts, thrombopoietin, immature platelet fraction, and mean pla

68 utants and platelets from patients displayed thrombopoietin-independent phosphorylation of signal tra

69 activity is necessary but not sufficient for thrombopoietin-induced cell cycle progression.

70 hosphatidylinositol 3-kinase is required for thrombopoietin-induced cell cycling in BaF3/Mpl cells an

71 R-34a expression is also up-regulated during thrombopoietin-induced differentiation of CD34(+) hemato

72 ispensable for megakaryocytopoiesis, and for thrombopoietin-induced ERK1/2 activation in primary mega

73 y increase in A-Raf or B-Raf expression, and thrombopoietin-induced ERK1/2 phosphorylation is similar

74 theless, the absence of Raf-1 does not alter thrombopoietin-induced expansion of primary megakaryocyt

75 from human haematopoietic progenitor cells, thrombopoietin-induced megakaryocytic differentiation le

76 f significant stromal fibrosis in a model of thrombopoietin-induced myelofibrosis.

77 aF3/Mpl cells and megakaryocyte progenitors, thrombopoietin-induced phosphatidylinositol 3-kinase act

78 Here, we show that thrombopoietin induces phosphatidylinositol 3-kinase and

79 tors for IL-2 (JAK1- and JAK3-dependent) and thrombopoietin (JAK2-dependent), demonstrating the high

80 tact with hECs and minimal concentrations of thrombopoietin/Kit-ligand/Flt3-ligand resulted in a 400-

81 Plasma thrombopoietin levels inversely correlated with platelet

82 Serum thrombopoietin levels overlapped in mutant vs control mi

83 yrosine kinase JAK2 and elevated circulating thrombopoietin levels.

84 Thrombopoietin may increase the number of hematopoietic

85 An observed increase in thrombopoietin-mediated Akt phosphorylation in the trunc

86 illustrate an involvement for GP Ibalpha in thrombopoietin-mediated events of megakaryocyte prolifer

87 tients, resulting in diminished thrombin and thrombopoietin-mediated integrin alpha(IIb)beta(3) activ

88 In addition, thrombopoietin-mediated JAK2 phosphorylation was unchang

89 a/14-3-3xi/PI-3 kinase complex in regulating thrombopoietin-mediated responses.

90 unosuppression to determine whether the oral thrombopoietin mimetic eltrombopag (Promacta) can improv

91 ponse may also occur with alemtuzumab or the thrombopoietin mimetic eltrombopag in refractory AA.

92 hGH enhances the effect of a tandem dimer of thrombopoietin mimetic peptide (dTMP) on thrombopoiesis,

93 ed the efficacy and safety of romiplostim, a thrombopoietin mimetic, in patients with low- or interme

94 Romiplostim, a thrombopoietin mimetic, increases platelet counts in pat

95 Eltrombopag belongs to a new class of thrombopoietin-mimetic drugs that raise platelet counts

96 Romiplostim, a thrombopoietin-mimetic peptibody, increases and maintain

97 ated by the therapeutic effectiveness of the thrombopoietin mimetics in ITP.

98 te-macrophage colony-stimulating factor, and thrombopoietin); most have proinflammatory effects.

99 tly reported increased in vivo activities of thrombopoietin (Mpl ligand) and leptin following carbohy

100 cluding receptors for erythropoietin (EPOR), thrombopoietin (MPL), and granulocyte colony-stimulating

101 cture a small upstream open reading frame in thrombopoietin mRNA, and the resulting overproduction of

102 is a loss-of-function variant that promotes thrombopoietin/myeloproliferative leukemia virus oncogen

103 in isolated MKs increased signaling via the thrombopoietin/myeloproliferative leukemia virus oncogen

104 megakaryocytic and erythroid progenitors by thrombopoietin or erythropoietin was unaffected.

105 When HEL cells were stimulated with thrombopoietin or phorbol 12-myristate 13-acetate (PMA),

106 2%) amplification cultures with two (Flt3L + thrombopoietin) or four cytokines (Flt3L + thrombopoieti

107 megakaryocytes in the presence or absence of thrombopoietin, or the development of megakaryocyte DNA

108 to be related to marrow injury or decreased thrombopoietin production.

109 bol-13-acetate and primary megakaryocytes by thrombopoietin promotes MKL1 nuclear localization.

110 growth factor receptor-1 (F36VFGFR1) and the thrombopoietin receptor (F36VMpl) induced a sustained ex

111 d to express a conditional derivative of the thrombopoietin receptor (F36Vmpl).

112 59457 (SB), a nonpeptidyl hydrazone class of thrombopoietin receptor (Mpl) agonist, revealed toxicity

113 5R/R938Q induced spontaneous growth of Ba/F3-thrombopoietin receptor (MPL) but not of Ba/F3-human rec

114 We have reported defective thrombopoietin receptor (Mpl) protein expression in MPD

115 Mutations of thrombopoietin, the thrombopoietin receptor (MPL), and the erythropoietin re

116 port here that amino acid substitutions in a thrombopoietin receptor (Mpl)--containing cell growth sw

117 ombopag (EP) is a small-molecule, nonpeptide thrombopoietin receptor (TPO-R) agonist that has been ap

118 ts before (n = 10) and during treatment with thrombopoietin receptor (TPO-R) agonists (n = 9).

119 Decreased expression of the thrombopoietin receptor (TPOR or MPL) on the cell surfac

120 ns participate in the activity states of the thrombopoietin receptor (TpoR), a type 1 cytokine recept

121 In the human thrombopoietin receptor (TpoR), a unique amphipathic RWQ

122 l, small-molecule, nonpeptide agonist of the thrombopoietin receptor (TpoR), being developed as a tre

123 ase 2 phosphorylation, initiated through the thrombopoietin receptor (TPOR/Mpl) activation, was affec

124 genic CALR mutants specifically activate the thrombopoietin receptor (TpoR/MPL).

125 xamine the in vivo effects of eltrombopag, a thrombopoietin receptor agonist (TPO-RA), on platelet fu

126 The thrombopoietin receptor agonist eltrombopag has been sho

127 The oral thrombopoietin receptor agonist eltrombopag is approved

128 Eltrombopag (ELT) is a thrombopoietin receptor agonist reported to decrease lab

129 The thrombopoietin receptor agonist romiplostim could be an

130 Romiplostim is a thrombopoietin receptor agonist that increases platelet

131 Eltrombopag is a small molecule thrombopoietin receptor agonist that might be a new opti

132 RE), we aimed to assess eltrombopag, an oral thrombopoietin receptor agonist, for thrombocytopenia (g

133 Eltrombopag, an oral thrombopoietin receptor agonist, increases platelet coun

134 We tested whether eltrombopag, a thrombopoietin receptor agonist, might be effective in i

135 Thrombopoietin receptor agonists (eltrombopag; romiplost

136 has changed with the advent of rituximab and thrombopoietin receptor agonists (TPO-RAs) as options fo

137 efficacy and safety, in particular, for the thrombopoietin receptor agonists and the occurrence of l

138 Thrombopoietin receptor agonists are reported to increas

139 ents respond to antithymocyte globulins, and thrombopoietin receptor agonists are under investigation

140 Tier 1 options (rituximab, thrombopoietin receptor agonists, low-dose corticosteroi

141 templating pregnancy while on treatment with thrombopoietin receptor agonists, rituximab, or mycophen

142 More recently, activating mutations in the thrombopoietin receptor and in JAK2 exon 12 have been id

143 A thrombopoietin receptor derivative that brings the proli

144 atic activating mutations in JAK2 and in the thrombopoietin receptor gene (MPL) in most patients with

145 al 5 to 10% have activating mutations in the thrombopoietin receptor gene (MPL).

146 a p.Lys39Asn amino acid substitution of the thrombopoietin receptor gene (p = 1.5 x 10(-11)).

147 a chemically induced dimerizer and modified thrombopoietin receptor has now allowed the expansion of

148 mutations of the erythropoietin receptor and thrombopoietin receptor have been identified in familial

149 e discovery of an activating mutation in the thrombopoietin receptor in JAK2-negative myelofibrosis a

150 resultant mice were compared with a Mpl-/- (thrombopoietin receptor knockout) thrombocytopenic murin

151 Endocytosis of the thrombopoietin receptor Mpl was impaired in Dnm2-null pl

152 e demonstrated that mutant CALR binds to the thrombopoietin receptor MPL, and that the positive elect

153 en OTT-MAL and an activating mutation of the thrombopoietin receptor myeloproliferative leukemia viru

154 miR-28 exerts negative effects on thrombopoietin receptor signaling and platelet formation

155 scribed, somatic, activating mutation in the thrombopoietin receptor that is sensitive to down-stream

156 Although the thrombopoietin receptor was discovered in 1991 and throm

157 this idea, the signaling domain of Mpl (the thrombopoietin receptor) was targeted to the plasma memb

158 expression of p21(Cip1), p27(Kip1), and the thrombopoietin receptor, known regulators of HSC self-re

159 nner in 1 of 3 genes: JAK2, CALR, or MPL The thrombopoietin receptor, MPL, is the key cytokine recept

160 tor, the erythropoietin receptor (EpoR), the thrombopoietin receptor, or the granulocyte colony-stimu

161 omerize with several other tagged receptors (thrombopoietin receptor, transforming growth factor beta

162 at from mice lacking c-Mpl (c-Mpl(-/-)), the thrombopoietin receptor.

163 P were randomly assigned to receive the oral thrombopoietin-receptor agonist eltrombopag (30, 50, or

164 Eltrombopag is an oral, non-peptide, thrombopoietin-receptor agonist that stimulates thrombop

165 Eltrombopag is a new, orally active thrombopoietin-receptor agonist that stimulates thrombop

166 immunosuppression, eltrombopag, a synthetic thrombopoietin-receptor agonist, led to clinically signi

167 The effects of eltrombopag, a thrombopoietin-receptor agonist, on platelet function in

168 Eltrombopag is an oral thrombopoietin-receptor agonist.

169 PURPOSE OF REVIEW: Thrombopoietin-receptor agonists (TPO-RAs) have been app

170 Stimulation of platelet production by thrombopoietin-receptor agonists (TPO-RAs) is an effecti

171 Combining an immunosuppressant therapy with thrombopoietin-receptor agonists may be a good strategy

172 combination of immunosuppressant therapy and thrombopoietin-receptor agonists that lasted for a media

173 er induction with erythropoietin, G-CSF, and thrombopoietin, respectively.

174 forms of the c-Mpl ligand--recombinant human thrombopoietin (rhTPO) and pegylated recombinant human m

175 Recombinant human thrombopoietin (rhTPO) increases platelets, and the peak

176 les exposed to SB, but not recombinant human thrombopoietin (rhTpo), in liquid suspension culture.

177 to 10 mum ABA does not increase recombinant thrombopoietin (rTpo)-dependent Mk differentiation or pl

178 nd germ-line-activating mutations affect the thrombopoietin signaling axis.

179 karyocytes to the endosteal niche depends on thrombopoietin signaling through the c-MPL receptor on m

180 ressed in hematopoietic cells and suppresses thrombopoietin signaling via its receptor myeloprolifera

181 In contrast, enhanced thrombopoietin signaling, conferred by enforced expressi

182 Treatment with recombinant human thrombopoietin significantly increased platelet count (m

183 + thrombopoietin) or four cytokines (Flt3L + thrombopoietin + stem cell factor + interleukin 3).

184 oncontact HUBEC cultures and the addition of thrombopoietin, stem cell factor (SCF), and macrophage c

185 /mpl, silencing of TRIB3 increased basal and thrombopoietin-stimulated megakaryocyte antigen expressi

186 Thrombopoietin stimulates extracellular signal-related k

187 itro to produce proplatelets, independent of thrombopoietin stimulation, and they responded to stimul

188 itself is tyrosine-phosphorylated following thrombopoietin stimulation.

189 -Mpl, the cellular receptor for the cytokine thrombopoietin, suggest that c-Mpl does not control HSC

190 In mouse models, increased hepatic thrombopoietin synthesis in response to tumor-derived in

191 of platelet-biased HSCs crucially depends on thrombopoietin, the primary extrinsic regulator of plate

192 de, with the cloning and characterization of thrombopoietin, the primary regulator of this process.

193 Mutations of thrombopoietin, the thrombopoietin receptor (MPL), and t

194 Thrombopoietin therapy can increase platelet counts in h

195 ets collected from healthy donors undergoing thrombopoietin therapy were safe and resulted in signifi

196 The interaction between thrombopoietin (THPO) and its receptor c-Mpl regulates d

197 the hereditary thrombocytosis induced by the thrombopoietin (THPO) receptor MPL P106L mutant remain u

198 Expression of the thrombopoietin (THPO) receptor MPL was elevated in leuke

199 Thrombopoietin (Thpo) signaling through the c-Mpl recept

200 ne, MPL, a homodimeric receptor activated by thrombopoietin (THPO), is mutated in myeloproliferative

201 ealed that Bcl-xL expression is regulated by thrombopoietin (THPO)/MPL-signaling induced by AE expres

202 ng identified mutations in the gene encoding thrombopoietin (THPO): THPO R99W, homozygous in affected

203 fied a novel homozygous missense mutation in thrombopoietin (THPO, c.112C>T) in both affected sibling

204 granules, and forming PPTs without exogenous thrombopoietin, thus identifying a novel and unexplored

205 Finally, we administered thrombopoietin to mice beginning 5 days before marrow ra

206 The binding of thrombopoietin to Mpl activates multiple kinase pathways

207 kt in BaF3/Mpl cells restored the ability of thrombopoietin to promote cell cycling in the presence o

208 g factor, stem cell factor, flt3 ligand, and thrombopoietin, to this SCEPF activity.

209 Thrombopoietin (TPO) acting via its receptor, the cellul

210 karyocyte production, signaling initiated by thrombopoietin (TPO) activation of its receptor, myelopr

211 that c-Cbl(-/-) HSCs are hyperresponsive to thrombopoietin (TPO) and display elevated levels of STAT

212 Recently, interactions between thrombopoietin (TPO) and its receptor, the myeloprolifer

213 We investigated the association of plasma thrombopoietin (TPO) and overall survival in 127 patient

214 ulxin, and the cytokine receptor Mpl agonist thrombopoietin (TPO) are able to induce activation of RA

215 Thrombopoietin (TPO) attracts much attention as an effec

216 Multiple lines of evidence indicate that thrombopoietin (TPO) contributes to the development of h

217 Here we show that thrombopoietin (TPO) cooperates with FLT3-L, inducing CD

218 In our previous studies we demonstrated that thrombopoietin (TPO) enhances levels of HOXB4 mRNA in pr

219 differentiated in a medium supplemented with thrombopoietin (TPO) for 18 days.

220 ition, BM from Cib1(-/-) mice, cultured with thrombopoietin (TPO) for 24 hours, produced more highly

221 vels are controlled by circulating levels of thrombopoietin (TPO) functioning to activate megakaryocy

222 etiology of this disease, we identified the thrombopoietin (Tpo) gene as a target of the SMRT-retino

223 Thrombopoietin (TPO) has been demonstrated as a crucial

224 The role of thrombopoietin (Tpo) in promoting hematopoiesis has been

225 Thrombopoietin (Tpo) is a glycoprotein growth factor tha

226 Thrombopoietin (TPO) is the major regulator of megakaryo

227 Thrombopoietin (Tpo) is the primary cytokine regulating

228 Thrombopoietin (TPO) is the primary regulator of platele

229 Finally, two thrombopoietin (Tpo) mimetics were approved by the FDA f

230 ets to the AMR induces hepatic expression of thrombopoietin (TPO) mRNA and protein, thereby regulatin

231 pffer cells, ultimately leading to increased thrombopoietin (TPO) production in the liver.

232 L), increased cell surface expression of the thrombopoietin (TPO) receptor (c-MPL) and enhanced proli

233 Here we show that loss of the thrombopoietin (TPO) receptor (MPL) significantly amelio

234 ut not CALRdelex9, specifically activate the thrombopoietin (TPO) receptor (MPL) to induce constituti

235 mbocythemia (ET) with mutations in JAK2, the thrombopoietin (TPO) receptor (MPL), and the calreticuli

236 ing through an abnormal interaction with the thrombopoietin (TPO) receptor (MPL).

237 pression of murine JAK2 V617F and the murine thrombopoietin (Tpo) receptor (TpoR, c-MPL) in hematopoi

238 The thrombopoietin (TPO) receptor c-Mpl, like other members

239 Mpl is the thrombopoietin (TPO) receptor.

240 on of these cells in the presence of dox and thrombopoietin (TPO) resulted in an exponential (at leas

241 elinexor causes thrombocytopenia by blocking thrombopoietin (TPO) signaling and therefore differentia

242 This pattern is associated with up-regulated thrombopoietin (TPO) signaling through mammalian target

243 Thrombopoietin (TPO) stimulates a network of intracellul

244 Multiple lines of evidence indicate that thrombopoietin (TPO) substantially impacts the number of

245 otein that dampens signaling by the cytokine thrombopoietin (Tpo) to limit HSC expansion.

246 The term thrombopoietin (TPO) was first coined in 1958 and used t

247 Serum thrombopoietin (TPO) was maintained at normal levels in

248 opoietin receptor was discovered in 1991 and thrombopoietin (TPO) was purified in 1994, the developme

249 design, antibody fragments (Fabs) that mimic thrombopoietin (TPO) were created.

250 IL-8, VEGF receptors VEGFR1 and VEGFR2, and thrombopoietin (TPO) were measured in plasma samples of

251 We have previously shown that thrombopoietin (TPO), a critical HSC regulator, ensures

252 Thrombopoietin (Tpo), acting through its receptor c-Mpl,

253 Thrombopoietin (Tpo), acting through the c-Mpl receptor,

254 in transcription factors, in the response to thrombopoietin (Tpo), and newly described developmentall

255 Up-regulation of survivin by thrombopoietin (Tpo), Flt3 ligand (FL), and stem cell fa

256 eloproliferative leukemia), the receptor for thrombopoietin (TPO), in T cells.

257 using low levels of stem cell factor (SCF), thrombopoietin (TPO), insulin-like growth factor 2 (IGF-

258 2-step differentiation process, regulated by thrombopoietin (TPO), on binding to its cognate receptor

259 some individuals treated with a recombinant thrombopoietin (TPO), pegylated recombinant human megaka

260 ) messenger RNA (mRNA) expression; (3) serum thrombopoietin (Tpo), stem cell factor (SCF), interleuki

261 Thrombopoietin (TPO), the c-Mpl ligand, is the primary p

262 Thrombopoietin (TPO), the critical regulator of platelet

263 Thrombopoietin (TPO), the primary regulator of platelet

264 Thrombopoietin (TPO), the primary regulator of platelet

265 Thrombopoietin (TPO), the primary regulator of thrombopo

266 We demonstrate that in the absence of thrombopoietin (TPO), tyrosine-unphosphorylated STAT5 (u

267 one marrow endothelial cells (BMECs) promote thrombopoietin (TPO)-independent platelet production.

268 ffect of an Src kinase inhibitor, SU6656, on thrombopoietin (TPO)-induced growth and differentiation.

269 Thrombopoietin (Tpo)-induced in vitro expansion of ES ce

270 own Lyn kinase to be a negative regulator of thrombopoietin (TPO)-induced proliferation.

271 Thrombopoietin (Tpo)-mediated activation of Lyn kinase,

272 s (HSCs) harboring DNA damage are rescued by thrombopoietin (TPO)-mediated DNA repair.1 It has been r

273 ain HSC homeostasis by positively regulating thrombopoietin (Tpo)-mediated Jak2 signaling.

274 We show that IFN-gamma reduces thrombopoietin (TPO)-mediated phosphorylation of signal

275 tion of miR-193b upon self-renewal promoting thrombopoietin (TPO)-MPL-STAT5 signalling.

276 induction of a luciferase reporter gene in a thrombopoietin (TPO)-responsive cell line resulted in th

277 In this study we demonstrate that thrombopoietin (TPO)-stimulated Src family kinases (SFKs

278 reaction of purified mouse MKs isolated from thrombopoietin (TPO)-treated bone marrow (BM) cultures i

279 ion signals after stimulation by its ligand, thrombopoietin (TPO).

280 adult hematopoietic microenvironment and to thrombopoietin (Tpo).

281 (CpG) demethylation that can be initiated by thrombopoietin (TPO).

282 imary mean of regulating the plasma level of thrombopoietin (TPO).

283 stromal cell derived factor-1a (SDF-1a), and thrombopoietin (TPO).

284 ting factor (GM-CSF), Steel factor (SLF), or thrombopoietin (TPO).

285 factor (SCF) + interleukin 7 (IL-7), or FL + thrombopoietin (Tpo).

286 cloned, and generated recombinant zebrafish thrombopoietin (Tpo).

287 Soluble Kit-ligand (sKitL), thrombopoietin (TPO, encoded by Thpo) and, to a lesser e

288 mbopoietic growth factors (recombinant human thrombopoietin [TPO] and pegylated recombinant human meg

289 F], insulinlike growth factor-1 [IGF-1], and thrombopoietin [TPO]); cytokines (tumor necrosis factor-

290 structed by either in vivo overexpression of thrombopoietin (TPOhigh mice) or megakaryocyte lineage r

291 e 2 (JAK2) is essential for signaling by the thrombopoietin (TpoR) and erythropoietin (EpoR) receptor

292 oped with the discovery that the recombinant thrombopoietins (TPOs) could enhance platelet production

293 tion of VEGFR-3 increased platelet counts in thrombopoietin-treated mice significantly and modulated

294 giopoietin-like 3 and IGF2, but also SCF and thrombopoietin, two other growth factors important for H

295 d; and the primary regulator of the process, thrombopoietin, was cloned and characterized and therape

296 Tumor-derived interleukin-6 and hepatic thrombopoietin were also linked to thrombocytosis in pat

297 No antibodies against romiplostim or thrombopoietin were detected.

298 tibodies to either romiplostim or endogenous thrombopoietin were seen.

299 ing and have lost the potentiating effect of thrombopoietin (which couples to JAK2) on this pathway.

300 on hepatocytes to enhance the production of thrombopoietin, which in turn interacts with its cognate